On the public citation graph
WFH Guidelines for the Management of Hemophilia, 3rd edition
0 signed · 2074 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archpedi.1989.02150210143035openalex-snapshot
Postdelivery Head Bleeding in Hemophilic Neonates
inferredcites →https://doi.org/10.1001/jama.285.18.2370openalex-snapshot
Prevalence of Diagnosed Atrial Fibrillation in Adults
inferredcites →https://doi.org/10.1007/s10897-015-9834-8openalex-snapshot
Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia
inferredcites →https://doi.org/10.1007/s10897-017-0112-9openalex-snapshot
“It was a lot Tougher than I Thought It would be”. A Qualitative Study on the Changing Nature of Being a Hemophilia Carrier
inferredcites →https://doi.org/10.1016/b978-0-323-46202-0.00032-7openalex-snapshot
Bleeding and the Management of Hemorrhagic Disorders in Pregnancy
inferredcites →https://doi.org/10.1016/s0029-7844(99)00280-xopenalex-snapshot
Spontaneous abortion–related deaths among women in the United States—1981–1991
inferredcites →https://doi.org/10.1046/j.1365-2516.1998.00179.xopenalex-snapshot
Causes of death in Canadians with haemophilia 1980-1995
inferredcites →https://doi.org/10.1046/j.1365-2516.1999.00288.xopenalex-snapshot
Counselling about diagnosis and inheritance of genetic bleeding disorders: haemophilia A and B
inferredcites →https://doi.org/10.1056/nejmoa1703068openalex-snapshot
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
inferredcites →https://doi.org/10.1093/europace/eus333openalex-snapshot
Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients
inferredcites →https://doi.org/10.1097/mph.0000000000001036openalex-snapshot
Prevalence of Hypertension (HTN) and Cardiovascular Risk Factors in a Hospitalized Pediatric Hemophilia Population
inferredcites →https://doi.org/10.1111/bjh.15606openalex-snapshot
Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study ERHEA
inferredcites →https://doi.org/10.1111/hae.12120openalex-snapshot
Attitudes and practices with regard to circumcision in haemophilia patients in Southern Iran
inferredcites →https://doi.org/10.1111/hae.12300openalex-snapshot
Pharmacokinetic analysis of anti‐hemophilic factor in the obese patient
inferredcites →https://doi.org/10.1111/hae.12528openalex-snapshot
Neonatal circumcision in severe haemophilia: a survey of paediatric haematologists at United States Hemophilia Treatment Centers
inferredcites →https://doi.org/10.1111/hae.12568openalex-snapshot
Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis
inferredcites →https://doi.org/10.1111/hae.12921openalex-snapshot
Haematuria is not a risk factor of hypertension or renal impairment in patients with haemophilia
inferredcites →https://doi.org/10.1111/hae.13214openalex-snapshot
Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study
inferredcites →https://doi.org/10.1111/hae.13291openalex-snapshot
Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines
inferredcites →https://doi.org/10.1111/hae.13323openalex-snapshot
Study of physical function in adolescents with haemophilia: The SO‐FIT study
inferredcites →https://doi.org/10.1111/hae.13448openalex-snapshot
Management of haemophilia carriers around the time of their delivery: Phenotypic variation requiring customization of management
inferredcites →https://doi.org/10.1111/hae.13668openalex-snapshot
Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: A National Inpatient Sample Study
inferredcites →https://doi.org/10.1111/j.1365-2141.1975.tb01859.xopenalex-snapshot
Detection of Carriers of Haemophilia: a ‘Blind’ Study
inferredcites →https://doi.org/10.1111/j.1365-2141.1990.tb07793.xopenalex-snapshot
Haemophilia protects against ischaemic heart disease: a study of risk factors
inferredcites →https://doi.org/10.1111/j.1365-2141.2010.08545.xopenalex-snapshot
Guideline on the management of haemophilia in the fetus and neonate*
inferredcites →https://doi.org/10.1111/j.1365-2516.2004.00943.xopenalex-snapshot
Consensus recommendations for use of central venous access devices in haemophilia
inferredcites →https://doi.org/10.1111/j.1365-2516.2006.01254.xopenalex-snapshot
Haemophilia and ageing
inferredcites →https://doi.org/10.1111/j.1365-2516.2006.01314.xopenalex-snapshot
The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01561.xopenalex-snapshot
Pregnancy in carriers of haemophilia
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01649.xopenalex-snapshot
Carrier testing in haemophilia A and B: adult carriers’ and their partners’ experiences and their views on the testing of young females
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.01987.xopenalex-snapshot
Co‐morbidity in the ageing haemophilia patient: the down side of increased life expectancy
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02030.xopenalex-snapshot
Comorbidities and bleeding pattern in elderly haemophilia A patients
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02187.xopenalex-snapshot
Alarmingly high prevalence of obesity in haemophilia in the state of Mississippi
inferredcites →https://doi.org/10.1111/j.1365-2516.2010.02417.xopenalex-snapshot
The impairment in daily life of obese haemophiliacs
inferredcites →https://doi.org/10.1111/j.1365-2516.2011.02558.xopenalex-snapshot
Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres
inferredcites →https://doi.org/10.1111/j.1365-2516.2011.02731.xopenalex-snapshot
Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System
inferredcites →https://doi.org/10.1111/j.1538-7836.2011.04499.xopenalex-snapshot
Factor VIII deficiency does not protect against atherosclerosis
inferredcites →https://doi.org/10.1111/j.1538-7836.2011.04542.xopenalex-snapshot
Reduced cardiovascular mortality in hemophilia despite normal atherosclerotic load
inferredcites →https://doi.org/10.1136/bmjopen-2018-022719openalex-snapshot
Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study
inferredcites →https://doi.org/10.1182/asheducation-2015.1.41openalex-snapshot
Managing older patients with hemophilia
inferredcites →https://doi.org/10.1182/blood-2005-09-3879openalex-snapshot
Bleeding in carriers of hemophilia
inferredcites →https://doi.org/10.1182/blood-2015-12-635094openalex-snapshot
How I treat patients with inherited bleeding disorders who need anticoagulant therapy
inferredcites →https://doi.org/10.1182/blood.v75.6.1267.1267openalex-snapshot
Hemorrhagic sequelae of immune thrombocytopenic purpura in human immunodeficiency virus-infected hemophiliacs
inferredcites →https://doi.org/10.1186/s13023-017-0660-yopenalex-snapshot
The cost of severe haemophilia in Europe: the CHESS study
inferredcites →https://doi.org/10.1186/s13023-019-1005-9openalex-snapshot
Hemophilia carrier’s awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d’Ivoire (Ivory Coast)
inferredcites →https://doi.org/10.5694/mja2.50123openalex-snapshot
Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4789895openalex-extracted
Maternal Microchimerism Promotes Tolerance Induction Toward Factor VIII in Severe Haemophilia a Children with Inhibitors
inferred← citeshttps://doi.org/10.1002/14651858.cd003429.pub5openalex-snapshot
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B
inferred← citeshttps://doi.org/10.1002/14651858.cd013634.pub2openalex-snapshot
Surgery for chronic arthropathy in people with haemophilia
inferred← citeshttps://doi.org/10.1002/14651858.cd014201openalex-snapshot
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B
inferred← citeshttps://doi.org/10.1002/14651858.cd014544openalex-snapshot
Non-clotting factor therapies for preventing bleeds in people with hemophilia
inferred← citeshttps://doi.org/10.1002/14651858.cd014544.pub2openalex-snapshot
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B
inferred← citeshttps://doi.org/10.1002/14651858.cd014544.pub3openalex-snapshot
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B
inferred← citeshttps://doi.org/10.1002/1545-5017.70442openalex-snapshot
Bleeding Outcomes After Adenotonsillar Surgery in Pediatric Patients With Hemophilia: Perioperative Management and Outcomes
inferred← citeshttps://doi.org/10.1002/9781119419525.ch26openalex-snapshot
Prophylaxis in von Willebrand disease
inferred← citeshttps://doi.org/10.1002/9781119665885.ch28openalex-snapshot
Inherited and Acquired Disorders of Haemostasis
inferred← citeshttps://doi.org/10.1002/9781119719809.ch37openalex-snapshot
Coagulation concentrates for inherited bleeding disorders
inferred← citeshttps://doi.org/10.1002/9781394292004.ch17openalex-snapshot
Inherited and Acquired Disorders of Coagulation
inferred← citeshttps://doi.org/10.1002/adfm.202402630openalex-snapshot
Exploring the Potential and Challenges of CRISPR Delivery and Therapeutics for Genetic Disease Treatment
inferred← citeshttps://doi.org/10.1002/ajh.27014openalex-snapshot
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
inferred← citeshttps://doi.org/10.1002/ajh.27602openalex-snapshot
2025 Clinical Trials Update on Hemophilia, VWD , and Rare Inherited Bleeding Disorders
inferred← citeshttps://doi.org/10.1002/ajh.27603openalex-snapshot
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND ‐1 Study
inferred← citeshttps://doi.org/10.1002/ajmg.c.31854openalex-snapshot
Genetic analysis for carrier diagnosis in hemophilia A and B in the Mexican population: 25 years of experience
inferred← citeshttps://doi.org/10.1002/btm2.10516openalex-snapshot
A polymer‐based systemic hemostat for managing uncontrolled bleeding
inferred← citeshttps://doi.org/10.1002/ccr3.70470openalex-snapshot
Hemophilia B With Intracranial Hemorrhage Rehabilitation in High‐Dependency Unit: A Case Report
inferred← citeshttps://doi.org/10.1002/ccr3.7439openalex-snapshot
Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa ( rIX‐FP ): A case report
inferred← citeshttps://doi.org/10.1002/ccr3.7558openalex-snapshot
Parapharyngeal hematoma following transesophageal echo in a patient with hemophilia A
inferred← citeshttps://doi.org/10.1002/ccr3.7901openalex-snapshot
Heart surgery in a pediatric patient with congenital heart disease and hemophilia B: A case report from Sudan
inferred← citeshttps://doi.org/10.1002/ccr3.8180openalex-snapshot
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID ‐19 pandemic
inferred← citeshttps://doi.org/10.1002/ccr3.9312openalex-snapshot
Successful immunosuppressive drug‐free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX : A case report
inferred← citeshttps://doi.org/10.1002/ccr3.9468openalex-snapshot
Combination of bolus and continuous infusion of factor VIII in a patient with severe hemophilia A undergoing on‐pump coronary artery bypass graft surgery
inferred← citeshttps://doi.org/10.1002/ctd2.70205openalex-snapshot
Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies
inferred← citeshttps://doi.org/10.1002/gin2.70061openalex-snapshot
Patient and Public Involvement Reporting Consistency: Analysis of 24 Clinical Practice Guidelines From 4 Countries
inferred← citeshttps://doi.org/10.1002/hcs2.70016openalex-snapshot
Surgical and Medical Co‐Management in an 82‐Year‐Old Patient With Hemophilia a Undergoing Pancreaticoduodenectomy
inferred← citeshttps://doi.org/10.1002/hsr2.1326openalex-snapshot
Methodological quality and recommendations of hemophilia clinical practice guidelines: A scoping review
inferred← citeshttps://doi.org/10.1002/hsr2.2003openalex-snapshot
Comparison between natural rubber knee support and sponge knee support on the protection of knee joint: A crossover randomized controlled study among patients with bleeding disorders
inferred← citeshttps://doi.org/10.1002/hsr2.70046openalex-snapshot
Proteomic exploration of potential blood biomarkers in haemophilic arthropathy
inferred← citeshttps://doi.org/10.1002/hsr2.71643openalex-snapshot
Interfacility Collaboration for Hemophilia Care in Japan: A Retrospective Database Study Using a Japanese Healthcare Claims Database
inferred← citeshttps://doi.org/10.1002/hsr2.71702openalex-snapshot
Rebalancing Hemostasis: Fitusiran as a First‐in‐Class RNAi Therapy in Hemophilia A and B
inferred← citeshttps://doi.org/10.1002/iub.70087openalex-snapshot
Balancing Promise and Peril: Hemophilia Gene Therapy Insights
inferred← citeshttps://doi.org/10.1002/jcla.24276openalex-snapshot
Evaluation of the Atellica COAG 360 coagulation analyzer in a specialized coagulation laboratory
inferred← citeshttps://doi.org/10.1002/jcla.24294openalex-snapshot
Multicenter performance evaluation and reference range determination of a new one‐stage factor VIII assay
inferred← citeshttps://doi.org/10.1002/jcph.70008openalex-snapshot
Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A
inferred← citeshttps://doi.org/10.1002/jha2.412openalex-snapshot
Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset
inferred← citeshttps://doi.org/10.1002/jha2.442openalex-snapshot
Non‐factor therapies for bleeding disorders: A primer for the general haematologist
inferred← citeshttps://doi.org/10.1002/jha2.503openalex-snapshot
Prophylaxis and hemophilia care in LATAM: Baring it all—Highlights from the CLAHT 2021 symposium
inferred← citeshttps://doi.org/10.1002/jha2.70367openalex-snapshot
Variables Affecting Periprocedural Haemostatic Response in Patients With Haemophilia: Real‐World Retrospective Study
inferred← citeshttps://doi.org/10.1002/joa3.12513openalex-snapshot
Third‐degree atrioventricular block and pacemaker implantation in a man with severe hemophilia A: A case report
inferred← citeshttps://doi.org/10.1002/jppr.1947openalex-snapshot
Fibrinogen concentrate use in the operating theatre at a quaternary hospital in Australia
inferred← citeshttps://doi.org/10.1002/jum.16084openalex-snapshot
Teleguidance for Patient Self‐Imaging of Hemophilic Joints Using Mobile Ultrasound Devices
inferred← citeshttps://doi.org/10.1002/jum.70142openalex-snapshot
Early Detection of Post‐Traumatic Heterotopic Ossification in Bleeding Disorders Using Ultrasound
inferred← citeshttps://doi.org/10.1002/mco2.70091openalex-snapshot
Gene therapy for genetic diseases: challenges and future directions
inferred← citeshttps://doi.org/10.1002/mgg3.2147openalex-snapshot
Molecular pathogenesis of a novel Met394Thr variant causing hemophilia B
inferred← citeshttps://doi.org/10.1002/pbc.29325openalex-snapshot
Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single‐center retrospective study
inferred← citeshttps://doi.org/10.1002/pbc.29902openalex-snapshot
Cerebral sinus venous thrombosis in children with inherited bleeding disorders: A case series
inferred← citeshttps://doi.org/10.1002/pbc.30264openalex-snapshot
Cost‐effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate–severe to severe hemophilia B in China
inferred← citeshttps://doi.org/10.1002/pbc.30759openalex-snapshot
Balancing anticoagulation and hemostasis in an infant with severe hemophilia A during cardiac transplantation: Review of the literature and development of a surgical protocol
inferred← citeshttps://doi.org/10.1002/pbc.31081openalex-snapshot
Practical challenges associated with efanesoctocog alfa (ALTUVIIIO) prophylaxis in a 19‐month‐old male with severe hemophilia A
inferred← citeshttps://doi.org/10.1002/pbc.31570openalex-snapshot
Improving Time to Bleeding Disorder Treatment in the Emergency Department
inferred← citeshttps://doi.org/10.1002/pbc.31712openalex-snapshot
Assessment of Clinical Characteristics and Sociocontextual Factors on Medication Adherence in Children and Adolescents With Hemophilia
inferred← citeshttps://doi.org/10.1002/pbc.31809openalex-snapshot
Describing Outpatient Physical Therapy Use Among Adolescents and Young Adults With Sickle Cell Disease: A Single‐Center Retrospective Study
inferred← citeshttps://doi.org/10.1002/pbc.32118openalex-snapshot
Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts
inferred← citeshttps://doi.org/10.1002/psp4.13159openalex-snapshot
PBPK modeling of recombinant factor IX Fc fusion protein ( rFIXFc ) and rFIX to characterize the binding to type 4 collagen in the extravascular space
inferred← citeshttps://doi.org/10.1002/rth2.12488openalex-snapshot
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
inferred← citeshttps://doi.org/10.1002/rth2.12498openalex-snapshot
Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates
inferred← citeshttps://doi.org/10.1002/rth2.12519openalex-snapshot
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
inferred← citeshttps://doi.org/10.1002/rth2.12552openalex-snapshot
Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
inferred← citeshttps://doi.org/10.1002/rth2.12561openalex-snapshot
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
inferred← citeshttps://doi.org/10.1002/rth2.12562openalex-snapshot
Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
inferred← citeshttps://doi.org/10.1002/rth2.12565openalex-snapshot
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
inferred← citeshttps://doi.org/10.1002/rth2.12576openalex-snapshot
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
inferred← citeshttps://doi.org/10.1002/rth2.12586openalex-snapshot
The intersection of vector biology, gene therapy, and hemophilia
inferred← citeshttps://doi.org/10.1002/rth2.12601openalex-snapshot
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
inferred← citeshttps://doi.org/10.1002/rth2.12602openalex-snapshot
Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
inferred← citeshttps://doi.org/10.1002/rth2.12613openalex-snapshot
Project GYM: A randomized feasibility study investigating effect on motivation of personal trainer‐led exercise in young men with hemophilia
inferred← citeshttps://doi.org/10.1002/rth2.12621openalex-snapshot
Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
inferred← citeshttps://doi.org/10.1002/rth2.12622openalex-snapshot
Fitness enhances psychosocial well‐being and self‐confidence in young men with hemophilia: Results from Project GYM
inferred← citeshttps://doi.org/10.1002/rth2.12639openalex-snapshot
Movement behavior in hemophilia—from medicalized training approaches toward an active lifestyle
inferred← citeshttps://doi.org/10.1002/rth2.12661openalex-snapshot
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
inferred← citeshttps://doi.org/10.1002/rth2.12670openalex-snapshot
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
inferred← citeshttps://doi.org/10.1002/rth2.12674openalex-snapshot
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
inferred← citeshttps://doi.org/10.1002/rth2.12685openalex-snapshot
First experience of a hemophilia monitoring platform: florio HAEMO
inferred← citeshttps://doi.org/10.1002/rth2.12686openalex-snapshot
Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
inferred← citeshttps://doi.org/10.1002/rth2.12690openalex-snapshot
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
inferred← citeshttps://doi.org/10.1002/rth2.12695openalex-snapshot
Impact of novel hemophilia therapies around the world
inferred← citeshttps://doi.org/10.1002/rth2.12725openalex-snapshot
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
inferred← citeshttps://doi.org/10.1002/rth2.12731openalex-snapshot
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
inferred← citeshttps://doi.org/10.1002/rth2.12741openalex-snapshot
Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
inferred← citeshttps://doi.org/10.1002/rth2.12760openalex-snapshot
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
inferred← citeshttps://doi.org/10.1002/rth2.12777openalex-snapshot
Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
inferred← citeshttps://doi.org/10.1002/rth2.12794openalex-snapshot
Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation
inferred← citeshttps://doi.org/10.1002/rth2.12799openalex-snapshot
Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
inferred← citeshttps://doi.org/10.1002/rth2.12800openalex-snapshot
Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes
inferred← citeshttps://doi.org/10.1002/rth2.12825openalex-snapshot
Burden of congenital hemophilia A requiring treatment in Japan: The HIKOBOSHI study
inferred← citeshttps://doi.org/10.1007/978-1-0716-3175-1_37openalex-snapshot
A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B
inferred← citeshttps://doi.org/10.1007/978-1-0716-3175-1_39openalex-snapshot
Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-71113-9_3-1openalex-snapshot
Predisposing Genetic Variants and Potent Genetic Mutations in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_11openalex-snapshot
Assessment of Joint Health and Outcome Measures in Hemophilia
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_12openalex-snapshot
Musculoskeletal Medicine in Hemophilia (Including Pain Control)
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_19openalex-snapshot
A Summary of the Recent Recommendations of the World Federation of Hemophilia
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_3openalex-snapshot
Inhibitors in Hemophilia A
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_4openalex-snapshot
Immune Tolerance Induction in Patients with Hemophilia A
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_6openalex-snapshot
Inhibitors in Hemophilia B
inferred← citeshttps://doi.org/10.1007/978-3-031-32046-0_29-1openalex-snapshot
Hemophilia and the Impact of Treatment Regimens: Interlinking Quality of Life Measures
inferred← citeshttps://doi.org/10.1007/978-3-031-32046-0_30-1openalex-snapshot
Quality of Life in Hemophilia
inferred← citeshttps://doi.org/10.1007/978-3-031-43156-2_13openalex-snapshot
Congenital Factor XI Deficiency, Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/978-3-031-43156-2_5openalex-snapshot
Hemophilia B: Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/978-3-031-73363-5_29openalex-snapshot
Hemophilia and the Impact of Treatment Regimens: Interlinking Quality of Life Measures
inferred← citeshttps://doi.org/10.1007/978-3-031-73363-5_30openalex-snapshot
Quality of Life in Hemophilia
inferred← citeshttps://doi.org/10.1007/978-3-031-76882-8_3openalex-snapshot
Predisposing Genetic Variants and Potent Genetic Mutations in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-032-09817-7_6openalex-snapshot
Hematology Management After Cardiac Surgery: Postoperative Care
inferred← citeshttps://doi.org/10.1007/978-3-032-13858-3_23openalex-snapshot
Coagulation Factor Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-032-13858-3_45openalex-snapshot
Management of the Surgical Patient with Thrombotic and Bleeding Diathesis
inferred← citeshttps://doi.org/10.1007/978-3-032-22660-0_29openalex-snapshot
Coagulopathies and Thrombocytopenia
inferred← citeshttps://doi.org/10.1007/978-3-032-26713-9_13openalex-snapshot
Dental Management of Persons with Hemophilia
inferred← citeshttps://doi.org/10.1007/978-3-032-26713-9_2openalex-snapshot
Fundamentals of Normal Hemostasis
inferred← citeshttps://doi.org/10.1007/978-3-032-26713-9_27openalex-snapshot
Local Hemostatic Agents and Measures
inferred← citeshttps://doi.org/10.1007/978-3-642-54676-1_94-3openalex-snapshot
Angeborene und erworbene Hämophilie
inferred← citeshttps://doi.org/10.1007/978-3-662-53390-1_6-2openalex-snapshot
Perioperatives Management von Gerinnungsstörungen bei Kindern und Jugendlichen
inferred← citeshttps://doi.org/10.1007/978-3-662-60880-7_150openalex-snapshot
Plasmatische Gerinnungsstörungen mit Blutungsneigung
inferred← citeshttps://doi.org/10.1007/978-3-662-61379-5_150-1openalex-snapshot
Plasmatische Gerinnungsstörungen mit Blutungsneigung
inferred← citeshttps://doi.org/10.1007/978-3-662-61379-5_150-2openalex-snapshot
Plasmatische Gerinnungsstörungen mit Blutungsneigung
inferred← citeshttps://doi.org/10.1007/978-3-662-66303-5_9openalex-snapshot
Antithrombotische Therapie
inferred← citeshttps://doi.org/10.1007/978-3-662-68371-2_9openalex-snapshot
Antithrombotische Therapie
inferred← citeshttps://doi.org/10.1007/978-3-662-70594-0_9openalex-snapshot
Antithrombotische Therapie
inferred← citeshttps://doi.org/10.1007/978-3-662-71825-4_23openalex-snapshot
Angeborene plasmatische Gerinnungsstörungen einschließlich von-Willebrand-Syndrom
inferred← citeshttps://doi.org/10.1007/978-3-662-72738-6_9openalex-snapshot
Antithrombotische Therapie
inferred← citeshttps://doi.org/10.1007/978-981-16-6494-6_6openalex-snapshot
Haematological Prehabilitation
inferred← citeshttps://doi.org/10.1007/978-981-92-1167-8_19openalex-snapshot
Comprehensive Management of Hemophilia, Including Recent Therapeutic Advances
inferred← citeshttps://doi.org/10.1007/978-981-97-4098-7_16openalex-snapshot
Regional Anaesthesia and Coagulation Disorder
inferred← citeshttps://doi.org/10.1007/978-981-99-5683-8_63openalex-snapshot
Pharmacotherapy of Perioperative Bleeding
inferred← citeshttps://doi.org/10.1007/s00112-022-01524-6openalex-snapshot
6 Monate/m mit ungewöhnlichen blauen Flecken
inferred← citeshttps://doi.org/10.1007/s00256-024-04652-0openalex-snapshot
Quantitative MRI assessment of joint effusion using T2-relaxometry at 3 Tesla: a feasibility and reproducibility study
inferred← citeshttps://doi.org/10.1007/s00259-021-05541-7openalex-snapshot
The EANM guideline for radiosynoviorthesis
inferred← citeshttps://doi.org/10.1007/s00261-026-05610-1openalex-snapshot
A primer on the imaging approach to acute gastrointestinal bleeding
inferred← citeshttps://doi.org/10.1007/s00277-023-05134-4openalex-snapshot
Pain: a neglected symptom in hemophilia
inferred← citeshttps://doi.org/10.1007/s00277-023-05287-2openalex-snapshot
Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders
inferred← citeshttps://doi.org/10.1007/s00277-023-05453-6openalex-snapshot
Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
inferred← citeshttps://doi.org/10.1007/s00277-024-05992-6openalex-snapshot
Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia
inferred← citeshttps://doi.org/10.1007/s00277-024-06178-wopenalex-snapshot
mBAT: a newly developed mobile application for self-screening of pediatric bleeding disorders – a multi-center study
inferred← citeshttps://doi.org/10.1007/s00277-025-06265-6openalex-snapshot
Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience
inferred← citeshttps://doi.org/10.1007/s00277-025-06552-2openalex-snapshot
Analysis of the current situation and influencing factors of home treatment for children with hemophilia in China
inferred← citeshttps://doi.org/10.1007/s00277-025-06557-xopenalex-snapshot
Updated Egyptian national guidelines for management of hemophilia A in children & adolescents
inferred← citeshttps://doi.org/10.1007/s00277-025-06723-1openalex-snapshot
From pharmacokinetic-guided FVIII prophylaxis to low-dose Emicizumab prophylaxis: a pilot study revealed a flush of hope
inferred← citeshttps://doi.org/10.1007/s00296-026-06162-9openalex-snapshot
The biomarkers uCTX-II, CS846 and IGF-1 are associated with clinical and ultrasound scores in haemophilic arthropathy: a cross-sectional study
inferred← citeshttps://doi.org/10.1007/s00431-026-06872-zopenalex-snapshot
Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors
inferred← citeshttps://doi.org/10.1007/s00467-026-07429-wopenalex-snapshot
A rare but misleading cause of hematuria in hemophilia A: renal pelvic hemorrhage mimicking tumor
inferred← citeshttps://doi.org/10.1007/s00508-024-02368-8openalex-snapshot
Gene therapy: principles, challenges and use in clinical practice
inferred← citeshttps://doi.org/10.1007/s00508-024-02370-0openalex-snapshot
Hämophilie-Behandlung in Österreich
inferred← citeshttps://doi.org/10.1007/s00590-023-03586-yopenalex-snapshot
The effect of HIV prevalence, CD4 counts and disease severity on the outcome of total knee arthroplasty for haemophilic arthropathy: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00940-022-3356-xopenalex-snapshot
Hämophilie - eine Aufgabe für die Schmerzmedizin?
inferred← citeshttps://doi.org/10.1007/s10238-024-01528-4openalex-snapshot
Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis
inferred← citeshttps://doi.org/10.1007/s10654-026-01389-zopenalex-snapshot
Life expectancy of people with hemophilia in France in 2022
inferred← citeshttps://doi.org/10.1007/s11239-022-02741-2openalex-snapshot
Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery
inferred← citeshttps://doi.org/10.1007/s11657-022-01203-9openalex-snapshot
Pathogenesis and treatment of osteoporosis in patients with hemophilia
inferred← citeshttps://doi.org/10.1007/s11910-023-01313-yopenalex-snapshot
Neurological Complications Associated with Hereditary Bleeding Disorders
inferred← citeshttps://doi.org/10.1007/s12033-025-01464-yopenalex-snapshot
Transforming Hemophilia Management: Lessons from Gene Therapy Clinical Trials
inferred← citeshttps://doi.org/10.1007/s12098-025-05696-3openalex-snapshot
Effective but Elusive: Emicizumab for Hemophilia A in India
inferred← citeshttps://doi.org/10.1007/s12098-025-05886-zopenalex-snapshot
Continuum of Care for Hemophilia: The Story of India
inferred← citeshttps://doi.org/10.1007/s12185-021-03104-yopenalex-snapshot
Cardiovascular risk factors among adult patients with haemophilia
inferred← citeshttps://doi.org/10.1007/s12185-022-03456-zopenalex-snapshot
Iliopsoas haemorrhage complicated by femoral neuropathy in patients with haemophilia: a case series report
inferred← citeshttps://doi.org/10.1007/s12185-022-03503-9openalex-snapshot
Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy
inferred← citeshttps://doi.org/10.1007/s12185-023-03679-8openalex-snapshot
Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study
inferred← citeshttps://doi.org/10.1007/s12185-024-03823-yopenalex-snapshot
Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A
inferred← citeshttps://doi.org/10.1007/s12185-025-04075-0openalex-snapshot
Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries
inferred← citeshttps://doi.org/10.1007/s12185-026-04182-6openalex-snapshot
Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort
inferred← citeshttps://doi.org/10.1007/s12185-026-04289-wopenalex-snapshot
Current perspectives on non-factor therapies for hemophilia
inferred← citeshttps://doi.org/10.1007/s12185-026-04296-xopenalex-snapshot
Cardiovascular events in aging Japanese people with hemophilia: a 3-year interim analysis of the ADVANCE Japan cohort
inferred← citeshttps://doi.org/10.1007/s12288-022-01539-9openalex-snapshot
Inhibitor; An Uncommon But Vexing Challenge In North Indian Patients With Hemophilia A
inferred← citeshttps://doi.org/10.1007/s12288-022-01587-1openalex-snapshot
Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
inferred← citeshttps://doi.org/10.1007/s12288-022-01588-0openalex-snapshot
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
inferred← citeshttps://doi.org/10.1007/s12288-023-01730-6openalex-snapshot
Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1007/s12288-025-02002-1openalex-snapshot
Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels
inferred← citeshttps://doi.org/10.1007/s12288-025-02186-6openalex-snapshot
Nonacog Beta Pegol (N9-Gp) Prophylaxis in Pediatric Patients with Severe Hemophilia B: A Single Center Real World Experience
inferred← citeshttps://doi.org/10.1007/s12288-026-02430-7openalex-snapshot
Clinical Profile, Inhibitor Status and Intragenic Polymorphism Analysis in Hemophilia A: A Cohort Study from Eastern India
inferred← citeshttps://doi.org/10.1007/s12288-026-02450-3openalex-snapshot
Achieving Successful Surgical Outcomes in Patients with Congenital Bleeding Disorders: Experience from a Resource-Limited Setting
inferred← citeshttps://doi.org/10.1007/s12288-026-02532-2openalex-snapshot
Clot Waveform Analysis of Activated Partial Thromboplastin Time for Evaluating Hemostatic Abnormalities and Severity in Hemophilia: A Cross-Sectional Study of Fibrin Formation and Thrombin Dynamics
inferred← citeshttps://doi.org/10.1007/s12325-020-01599-1openalex-snapshot
Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
inferred← citeshttps://doi.org/10.1007/s12325-021-01853-0openalex-snapshot
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
inferred← citeshttps://doi.org/10.1007/s12325-022-02220-3openalex-snapshot
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
inferred← citeshttps://doi.org/10.1007/s12325-023-02559-1openalex-snapshot
Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries
inferred← citeshttps://doi.org/10.1007/s12325-024-02786-0openalex-snapshot
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
inferred← citeshttps://doi.org/10.1007/s12325-024-02834-9openalex-snapshot
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
inferred← citeshttps://doi.org/10.1007/s12325-024-02841-wopenalex-snapshot
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
inferred← citeshttps://doi.org/10.1007/s12325-024-02956-0openalex-snapshot
Clinical and Humanistic Burden of Non-inhibitor Haemophilia A in Five European Countries: Insights from the CHESS II Study
inferred← citeshttps://doi.org/10.1007/s12325-024-03031-4openalex-snapshot
Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors
inferred← citeshttps://doi.org/10.1007/s12325-024-03032-3openalex-snapshot
Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors
inferred← citeshttps://doi.org/10.1007/s12325-025-03131-9openalex-snapshot
Application of a Value Framework to Determine the Value of Prophylaxis Versus On-Demand Treatment in Adults with Hemophilia A in China
inferred← citeshttps://doi.org/10.1007/s12325-025-03303-7openalex-snapshot
Real-World Prophylaxis Outcomes with rIX-FP and rFIXFc for Males with Hemophilia B: Pooled Analysis of Medical Chart Data from Germany and Italy
inferred← citeshttps://doi.org/10.1007/s12325-025-03336-yopenalex-snapshot
Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany
inferred← citeshttps://doi.org/10.1007/s12325-025-03339-9openalex-snapshot
Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency
inferred← citeshttps://doi.org/10.1007/s12325-025-03368-4openalex-snapshot
Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data
inferred← citeshttps://doi.org/10.1007/s12325-026-03556-wopenalex-snapshot
Estimating the Impact of Hemophilia A Treatment Administration on Patient Health Utility: Combining a Discrete Choice Experiment with Time Trade-Off Method
inferred← citeshttps://doi.org/10.1007/s12325-026-03560-0openalex-snapshot
A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the PREDICT Study
inferred← citeshttps://doi.org/10.1007/s12325-026-03583-7openalex-snapshot
Non-factor Therapies in Hemophilia: Mechanisms, Clinical Evidence, Patient Management, and Future Perspectives
inferred← citeshttps://doi.org/10.1007/s13312-024-3140-1openalex-snapshot
The Last 50 years of Hemophilia Care: A Golden Era
inferred← citeshttps://doi.org/10.1007/s13318-024-00876-6openalex-snapshot
Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate
inferred← citeshttps://doi.org/10.1007/s15004-025-1250-0openalex-snapshot
Unklare Blutungsneigung – wie eine sinnvolle Abklärung gelingt
inferred← citeshttps://doi.org/10.1007/s40122-021-00345-xopenalex-snapshot
Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy
inferred← citeshttps://doi.org/10.1007/s40140-024-00635-yopenalex-snapshot
Perioperative Management of Hemophilia Patients
inferred← citeshttps://doi.org/10.1007/s40258-024-00932-xopenalex-snapshot
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA
showing the first 200 of 2026 · page through all 2026
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.